The trial also revealed statistically significant and clinically meaningful gains in key patient-reported outcomes
The acquisition of AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) positions Bayer at the forefront of cardiac amyloidosis diagnostics
Preclinical studies show that 4P004 modulates multiple biological markers across the joint, potentially slowing structural damage while improving function
Vanda strongly disputes the FDA’s reasoning
Nxera will take full responsibility for regulatory approvals, clinical development where required, manufacturing and commercialization in the licensed territories
The approval is backed by data showing deep, durable responses and manageable tolerability
The current two-vial format requires healthcare professionals to mix a lyophilised antigen with a liquid adjuvant before administration
The approval follows robust data from the SWIFT and ANCHOR Phase III trials
Subscribe To Our Newsletter & Stay Updated